Brooks Laboratories Ltd
Wed 30/04/2025,15:48:36 | NSE : BROOKS
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 136.65
Previous Close
₹ 133.94
Volume
8961
Mkt Cap ( Rs. Cr)
₹389.13
High
₹ 136.65
Low
₹ 129.00
52 Week High
₹ 198.86
52 Week Low
₹ 73.25
Book Value Per Share
₹ 21.19
Dividend Yield
0.00
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Brooks Laboratories Ltd
Your Vote -
Buy
22.22%
Hold
5.56%
Sell
72.22%
22.22%
36 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
100%
Sell Order Quantity
0%
Bid Price
Qty
139.77
605
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
605
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Brooks Laboratories Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Brooks Laboratories - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
-
Brooks Laboratories - Intimation Of Update In Registrar And Transfer Agent (RTA) Contact Details
-
Brooks Laboratories - Updates
-
Brooks Laboratories has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025
-
Brooks Laboratories - Disclosure under SEBI Takeover Regulations
-
Brooks Laboratories - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Brooks Laboratories - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Brooks Laboratories - Trading Window-XBRL
-
Brooks Laboratories - Trading Window
-
Brooks Laboratories - Reply to Clarification- Financial results
-
Brooks Laboratories - Clarification - Financial Results
-
Brooks Laboratories - Integrated Filing (Financial) For The Quarter And Nine Months Ended 31St December, 2024 (Revised).
-
Brooks Laboratories - Integrated Filing (Financial) For The Quarter And Nine Months Ended 31St December, 2024 (Revised).
-
Brooks Laboratories - General Updates
-
Brooks Laboratories - Outcome Of Board Meeting (Revised).
-
Brooks Laboratories - Updates
-
Brooks Laboratories - Copy of Newspaper Publication
-
Brooks Laboratories has submitted to BSE the Shareholding Pattern for the Period Ended January 29, 2025
-
Brooks Laboratories - Integrated Filing- Financial
-
Brooks Laboratories - Integrated Filing (Financial)
-
Brooks Laboratories Q3 net profit up 24.14% at Rs 0.72 cr
-
Brooks Laboratories - Financial Result Updates
-
Brooks Laboratories - Outcome of Board Meeting
-
Brooks Laboratories - Unaudited Financial Results, Both Standalone And Consolidated, For The Quarter And Nine Months Ended 31
-
Brooks Laboratories - Board Meeting Outcome for Board Meeting Outcome Under Regulation 30 & Regulation 33 Of SEBI (Listing O
-
Brooks Laboratories - Board Meeting Intimation
-
Brooks Laboratories - Board Meeting Intimation for Intimation Under Regulation 29 Of The SEBI (Listing Obligation And Disclos
Key fundamentals
Evaluate the intrinsic value of Brooks Laboratories Ltd stock
Name | March-24 | March-23 | March-22 | March-21 | March-20 |
---|---|---|---|---|---|
Assets | 74.5735 | 62.4424 | 69.9259 | 72.3712 | 122.4256 |
Liabilities | 74.5735 | 62.4424 | 69.9259 | 72.3712 | 122.4256 |
Equity | 26.2467 | 24.7028 | 24.7028 | 24.7028 | 24.7028 |
Gross Profit | 3.2173 | -5.8143 | 1.8744 | 0.7638 | -3.9221 |
Net Profit | 1.5287 | -8.1912 | 0.666 | -15.5876 | -24.376 |
Cash From Operating Activities | -9.6806 | 0.5622 | 3.1235 | -0.8986 | -9.3887 |
NPM(%) | 1.92 | -14.74 | 0.86 | -20.17 | -34.97 |
Revenue | 79.4861 | 55.538 | 76.9672 | 77.2469 | 69.6885 |
Expenses | 76.2688 | 61.3523 | 75.0928 | 76.4831 | 73.6106 |
ROE(%) | 2.44 | -13.12 | 1.06 | -24.97 | -39.05 |
Corporate Action
XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
---|
Peers
Other companies within the same industry or sector that are comparable to Brooks Laboratories Ltd
Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
---|---|---|---|---|---|---|
Albert David Ltd | 825.75 | -1.80 | 11.65 | 75.91 | 1321.50 | 1.39 |
Lotus Eye Hospital and Institute Ltd | 81.22 | -0.17 | 338.42 | 276.59 | 14.01 | 0.62 |
Vaishali Pharma Ltd | 13.47 | -1.82 | 449.00 | 142.57 | 2.76 | 0.00 |
Astec Lifesciences Ltd | 685.90 | -1.03 | 0.00 | 260.80 | -687.11 | 0.00 |
Company Info
Our Company was incorporated vide a Certificate of Incorporation dated January 23, 2002 bearing CIN No. U24232PB2002PLC24910 under the Companies Act 1956 with the name `Brooks Laboratories Limited' by our promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan. We received our certificate of commencement of business on February 19, 2002, from the Registrar of Companies, Punjab, Himachal Pradesh & Chandigarh at Jalandhar. Our Company was initially promoted for manufacturing of latest molecules in Injectables, tablets and dry syrups for the domestic customers. Our Company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development ("R&D") centre at Baddi, Himachal Pradesh. Our Company started its commercial production in the month of June 2006. Our Company became profitable from the very first year of its production. This facility at Baddi is WHO-GMP and ISO 9001:2008 certified. The facility focuses on developing latest molecules in the niche segments and then selling it to various pharmaceutical marketing Companies. Before staring our company, our promoters were engaged in manufacturing of Pharmaceutical Formulations in their partnership firm namely Brooks Pharmaceuticals. The firm had a manufacturing facility at F-94, Industrial Area, Phase 7, Mohali, Punjab. The factory at Mohali had annual installed capacity of 30 Lacs Injectables, 300 Lacs Tablets and 15 Lacs Dry Syrups. Our promoters had a successful track record of running the manufacturing of formulations in the aforesaid firm, profitably for over 6 years. In order to take an advantage of the growing market and avail the tax and other benefits that were made available by the Government to set up a manufacturing facility at Baddi, our promoters decided incorporate our company Brooks Laboratories Ltd and set up a bigger and more sophisticated unit at Baddi, in Himachal Pradesh. Subsequently, the firm was dissolved in the month of December 2008. Further in years 2007 and 2008 to have a smooth transition from Brook Pharmaceuticals to Brooks Laboratories Ltd., Our Company paid/settled some dues to Creditors and Lenders of Brooks Pharmaceuticals aggregating to Rs. 151.79 Lacs. Later on to settle the above our Company purchased on book value certain assets (Fixed assets & Stocks) aggregating to Rs. 113.27 Lacs and received an aggregate sum of Rs. 38.52 Lacs from M/s. Brooks Pharmaceuticals, a partnership firm promoted by our Promoters, Mr. Atul Ranchal and Mr. Rajesh Mahajan. Key Events and Milestones January 23, 2002 Incorporation of Brooks Laboratories Limited. February 19,2002 Received certificate for commencement of business May 5, 2005 Commenced setting up of manufacturing facility at Baddi, Himachal Pradesh. April 10,2006 Manufacturing drugs license issued by the State Drugs Controlling and Licensing Authority, HP. April 30, 2005 Commissioning of R&D centre at Baddi May 20,2006 Completion of Commissioning of plant for manufacture of Tablets, capsules, Injections, Oral Liquids etc. May 30, 2006 Start of commercial production June 1, 2006 First PPI Formulation developed by the Company. October 27,2006 Obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. August 02, 2007 Received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Limited, Australia. April 30, 2008* Takeover of some of the Assets of M/s Brooks Pharmaceuticals, a partnership firm of Our Promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan by our Company. December 30, 2008 Dissolution of M/s Brooks Pharmaceuticals, a partnership firm of Our Promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan. January 06,2009 Micro Small Medium Enterprise (MSME) Registration Certificate issued by Directorate of Industries for Manufacturing/Assembling Injections, Capsules & Tabulates (Single Window Clearance Agency). April 7,2010 The manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health & Family Welfare, HP. July 27,2010 Received an ISO 9001:2008 Certificate from UKAS Quality Management, URS & IAF. 2012 --Registered Office of the Company has been shifted to Village Kishanpura, Nalagarh Road, Baddi, Distt. Solan, H.P 2013 -Mr. Bhaskar Sharma has been appointed as Additional Independent Director of the company. 2014 - Ms.Sonia Gupta has been appointed as Independent Director of the Company. 2015 -Brooks Laboratories - Shifting of Corporate Office to 5th Floor, Next to Hotel Courtyard Marriott, Andheri Kurla Road, Mumbai - 400093. 2016 -Brooks Laboratories gets manufacturing licence for Gujarat facility. 2023 -The company issued rights shares of Rs. 10 in the ratio of 1:16 at a premium of Rs. 65 per share.
Our Company was incorporated vide a Certificate of Incorporation dated January 23, 2002 bearing CIN No. U24232PB2002PLC24910 under the Companies Act 1956 with the name `Brooks Laboratories Limited' by our promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan. We received our certificate of commencement of business on February 19, 2002, from the Registrar of Companies, Punjab, Himachal Pradesh & Chandigarh at Jalandhar. Our Company was initially promoted for manufacturing of latest molecules in Injectables, tablets and dry syrups for the domestic customers. Our Company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development ("R&D") centre at Baddi, Himachal Pradesh. Our Company started its commercial production in the month of June 2006. Our Company became profitable from the very first year of its production. This facility at Baddi is WHO-GMP and ISO 9001:2008 certified. The facility focuses on developing latest molecules in the niche segments and then selling it to various pharmaceutical marketing Companies. Before staring our company, our promoters were engaged in manufacturing of Pharmaceutical Formulations in their partnership firm namely Brooks Pharmaceuticals. The firm had a manufacturing facility at F-94, Industrial Area, Phase 7, Mohali, Punjab. The factory at Mohali had annual installed capacity of 30 Lacs Injectables, 300 Lacs Tablets and 15 Lacs Dry Syrups. Our promoters had a successful track record of running the manufacturing of formulations in the aforesaid firm, profitably for over 6 years. In order to take an advantage of the growing market and avail the tax and other benefits that were made available by the Government to set up a manufacturing facility at Baddi, our promoters decided incorporate our company Brooks Laboratories Ltd and set up a bigger and more sophisticated unit at Baddi, in Himachal Pradesh. Subsequently, the firm was dissolved in the month of December 2008. Further in years 2007 and 2008 to have a smooth transition from Brook Pharmaceuticals to Brooks Laboratories Ltd., Our Company paid/settled some dues to Creditors and Lenders of Brooks Pharmaceuticals aggregating to Rs. 151.79 Lacs. Later on to settle the above our Company purchased on book value certain assets (Fixed assets & Stocks) aggregating to Rs. 113.27 Lacs and received an aggregate sum of Rs. 38.52 Lacs from M/s. Brooks Pharmaceuticals, a partnership firm promoted by our Promoters, Mr. Atul Ranchal and Mr. Rajesh Mahajan. Key Events and Milestones January 23, 2002 Incorporation of Brooks Laboratories Limited. February 19,2002 Received certificate for commencement of business May 5, 2005 Commenced setting up of manufacturing facility at Baddi, Himachal Pradesh. April 10,2006 Manufacturing drugs license issued by the State Drugs Controlling and Licensing Authority, HP. April 30, 2005 Commissioning of R&D centre at Baddi May 20,2006 Completion of Commissioning of plant for manufacture of Tablets, capsules, Injections, Oral Liquids etc. May 30, 2006 Start of commercial production June 1, 2006 First PPI Formulation developed by the Company. October 27,2006 Obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. August 02, 2007 Received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Limited, Australia. April 30, 2008* Takeover of some of the Assets of M/s Brooks Pharmaceuticals, a partnership firm of Our Promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan by our Company. December 30, 2008 Dissolution of M/s Brooks Pharmaceuticals, a partnership firm of Our Promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan. January 06,2009 Micro Small Medium Enterprise (MSME) Registration Certificate issued by Directorate of Industries for Manufacturing/Assembling Injections, Capsules & Tabulates (Single Window Clearance Agency). April 7,2010 The manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health & Family Welfare, HP. July 27,2010 Received an ISO 9001:2008 Certificate from UKAS Quality Management, URS & IAF. 2012 --Registered Office of the Company has been shifted to Village Kishanpura, Nalagarh Road, Baddi, Distt. Solan, H.P 2013 -Mr. Bhaskar Sharma has been appointed as Additional Independent Director of the company. 2014 - Ms.Sonia Gupta has been appointed as Independent Director of the Company. 2015 -Brooks Laboratories - Shifting of Corporate Office to 5th Floor, Next to Hotel Courtyard Marriott, Andheri Kurla Road, Mumbai - 400093. 2016 -Brooks Laboratories gets manufacturing licence for Gujarat facility. 2023 -The company issued rights shares of Rs. 10 in the ratio of 1:16 at a premium of Rs. 65 per share.
Read More
Parent Organisation
Brooks Laboratories Ltd.
Founded
23/01/2002
Managing Director
NSE Symbol
BROOKSBE
FAQ
The current price of Brooks Laboratories Ltd is ₹ 132.10.
The 52-week high for Brooks Laboratories Ltd is ₹ 136.65 and the 52-week low is ₹ 129.00.
The market capitalization of Brooks Laboratories Ltd is currently ₹ 389.13. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Brooks Laboratories Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Brooks Laboratories Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Brooks Laboratories Ltd shares.
The CEO of Brooks Laboratories Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.